Stevanato Group SpA (STVN)
23.33
+0.02
(+0.09%)
USD |
NYSE |
Dec 16, 16:00
23.40
+0.06
(+0.28%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.367B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -17.34% |
| Valuation | |
| PE Ratio | 50.04 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.294 |
| Price to Book Value | 4.311 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0578 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2603 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa. |
| URL | https://www.stevanatogroup.com |
| Investor Relations URL | https://ir.stevanatogroup.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Mar. 07, 2025 (est.) |
| Last Earnings Release | Nov. 05, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 04, 2024 |
Ratings
Profile
| Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa. |
| URL | https://www.stevanatogroup.com |
| Investor Relations URL | https://ir.stevanatogroup.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Mar. 07, 2025 (est.) |
| Last Earnings Release | Nov. 05, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 04, 2024 |